Prostate-specific antigen (PSA) has been the cornerstone of prostate cancer screening for decades. While PSA testing is widely available, it suffers from limited specificity -- elevated PSA can result from benign conditions such as prostate enlargement or infection, leading to unnecessary biopsies and overtreatment.
Standard biopsy approaches guided by transrectal ultrasound can also miss or undergrade clinically significant tumors because they do not always sample the most aggressive areas. More targeted methods, such as MRI-guided targeted biopsy (MRI-TB), improve detection but require sophisticated imaging infrastructure and expertise.
To address these limitations, researchers are increasingly turning to genomic and bioinformatic approaches -- studying the molecular characteristics of tumor cells -- to develop more precise diagnostic and prognostic tools. These approaches aim to identify specific biological signatures that distinguish aggressive cancers from indolent ones.
One key strategy involves analyzing differentially expressed genes (DEGs) -- genes that are switched on or off more strongly in cancer tissue than in normal tissue. Using publicly available databases like the Gene Expression Omnibus (GEO), researchers can compare expression profiles across large patient datasets to identify candidate biomarkers for diagnosis and prognosis.
Building on this, protein-protein interaction (PPI) network analysis identifies hub genes -- those that are most centrally connected to biological processes related to cancer. One study using this approach on 123 prostate cancer samples identified 11 hub genes and highlighted pathways including focal adhesion and drug metabolism that may underlie cancer development.
More recently, next-generation sequencing (NGS) -- particularly RNA sequencing (RNA-Seq) -- has enabled deeper and more detailed genomic profiling than traditional microarray technology. Using RNA-Seq combined with machine learning, researchers have identified transcriptomic biomarkers tied to Gleason stages, including genes such as PIAS3, UBE2V2, and EPB41L1 that are strongly associated with cancer progression.
An even more comprehensive approach is multi-omics data integration, which combines data from multiple molecular layers simultaneously -- including genomics (DNA), transcriptomics (RNA), epigenomics (DNA methylation), proteomics (proteins), and metabolomics (metabolites). Deep learning models integrating these five omics layers have been used to predict prostate cancer relapse with improved accuracy.
Microarray technology measures the relative expression of thousands of known genes simultaneously by hybridizing RNA to a chip containing pre-designed probes. It is cost-effective and has well-established protocols, but it can only detect transcripts for genes already known and included on the chip, offers limited sensitivity, and cannot capture alternative splicing events or novel transcripts.
RNA-Seq through NGS overcomes these limitations by sequencing RNA molecules directly. It can detect both known and unknown transcripts, provides quantitative data at higher resolution, and captures a broader range of transcriptomic events. However, it requires more complex computational preprocessing -- reads must be aligned to a reference genome and assembled into transcripts -- and it costs more than microarrays.
Multi-omics integration goes further by combining data from different biological measurement platforms into a unified analysis. This approach can yield a more comprehensive picture of disease, including various types of biomarkers. The drawbacks are substantial cost, the complexity of integrating heterogeneous data types, and the lack of a well-established standardized analytical framework across different omics platforms.
The current trend in prostate cancer bioinformatics is moving toward integrating multiple omics data sources to discover richer biomarker profiles. Rather than relying on any single genomic layer, combining transcriptomics, proteomics, and epigenomics together provides a more complete view of the molecular mechanisms driving cancer development and progression.
Looking further ahead, the authors envision integrating omics data with medical imaging data, including MRI, to build unified predictive models. This fusion of molecular biology and radiology could enable more accurate prediction of disease outcomes and better patient stratification -- identifying which patients need immediate treatment and which can be safely monitored.
As NGS technology becomes cheaper, genomic profiling is expected to become more accessible in routine clinical settings within a few years. Combined with AI-powered analysis, these tools may eventually transform prostate cancer diagnosis from a largely image- and biopsy-based process to one grounded in precise molecular characterization.
This editorial review highlights the rapid evolution of prostate cancer bioinformatics, from foundational microarray-based gene expression analysis to sophisticated multi-omics deep learning models. Each technological generation has added new layers of biological insight.
The identification of specific biomarker genes -- particularly hub genes in protein interaction networks and Gleason-stage-specific transcripts -- represents tangible progress toward blood- or tissue-based tests that could complement or eventually replace PSA in clinical decision-making.
The central challenge going forward is translating these research discoveries into validated clinical tools that perform reliably across diverse patient populations. Standardizing multi-omics data collection and analysis workflows, and validating findings in prospective studies, will be essential steps before these approaches can impact routine patient care.